Anifrolumab, a relatively recent monoclonal antibody, is creating considerable excitement within the healthcare community as a viable option for various inflammatory conditions. This innovative agent targets the IFN https://gorillasocialwork.com/story26986009/anifrolumab-a-promising-approach-for-self-reactive-diseases